TME Pharma NV
ALTME
Company Profile
Business description
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).
Contact
Max-Dohrn-Street 8-10
Berlin10589
DEUT: +49 307262470
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,021.90 | 60.20 | 0.76% |
| CAC 40 | 7,285.86 | 44.11 | -0.60% |
| DAX 40 | 21,205.86 | 105.16 | -0.49% |
| Dow JONES (US) | 39,142.23 | 527.16 | -1.33% |
| FTSE 100 | 8,275.66 | 0.06 | 0.00% |
| HKSE | 21,395.14 | 338.16 | 1.61% |
| NASDAQ | 16,286.45 | 20.71 | -0.13% |
| Nikkei 225 | 34,730.28 | 352.68 | 1.03% |
| NZX 50 Index | 12,118.99 | 51.07 | 0.42% |
| S&P 500 | 5,282.70 | 7.00 | 0.13% |
| S&P/ASX 200 | 7,819.10 | 60.20 | 0.78% |
| SSE Composite Index | 3,280.34 | 4.34 | 0.13% |